Table 8 Implications of the study for policy, practice and research: perspectives of quality assurance staff Implications for future research **Finding** Implications for policy Implications for practice Visit preparation There is the belief that visit Although staff believe this Wider evaluation and audit and self-inspection preparation and self-inspection aspect is done relatively of whether visit preparation activities undertaken activities are being undertaken, well, there is always room for and self inspection practices but is no policy around what improvement, and support of are in fact as common as this these procedures should best-practice needed. More study suggests. Understanding information may need to be what is undertaken and what constitute provided by pharmaceutical contribution self-inspection facility visits undertaken by makes so as to inform future international inspectors best practice in the developing world Inspection fees are Payment policies required Consistent and transparent Further exploration of the variable, followed by different views of inspectors and payment practices required fixed-fees, and this QA industry staff with respect to is different from the payment is warranted inspectors Policy to facilitate the use of IT The gap between what QA Wide-scale evaluation of Inspection required. QA staff have ideas staff expect to receive, what is communication and external inspection reports about what they expect to policy and normal practice to be recommendations through content analysis would receive and this needs to be aligned help to inform policy and considered for future policy improve current practice development. Policy around inspection report sharing is required Policy on ad hoc visiting Difficulties with More information provided by Wide-scale surveys of the required. Pros and cons need the pharmaceutical facility prior inspections barriers and facilitators to · ad hoc visiting to be considered. Visits by to inspection, particularly with efficient and effective inspection planning inspectors from authorities foreign inspectors. practices needed based on the outside of the country less likely Health authorities websites findings of this study time needed for the industry staff to inspector insight/ to be *ad hoc*; joint policy may need to be developed in light understand GMP requirements. experience of this. This practice to be put in place Training and development and supported by regulatory policy required to inform policy. Workshops to be provided inspector training by regulatory authorities for pharmaceutical facilities to explain GMP compliance and marketing authorization requirements. Appropriate amounts of time needs to be allocated by inspectors and QA staff